Citius Oncology, Inc. (CTOR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 27, 2025, covers events occurring at Citius Oncology, Inc.'s 2025 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cranford, NJ.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
- Stock Incentive Plan Amendment: Stockholders approved an amendment to the 2024 Omnibus Stock Incentive Plan, increasing the authorized share pool from 15,000,000 to 30,000,000 shares.
- Director Elections: Stockholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms expiring in 2028.
- Auditor Ratification: Stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ended September 30, 2025.
Voting Results
| Proposal / Nominee | For | Against / Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Myron Holubiak (Director) | 74,305,221 | 36,554 | - | 3,462,017 |
| Joel Mayersohn (Director) | 74,312,668 | 29,107 | - | 3,462,017 |
| Stock Plan Amendment | 74,220,840 | 106,247 | 14,688 | 3,462,017 |
| Auditor Ratification | 77,690,844 | 36,459 | 76,489 | 0 |
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding future financial performance or operational strategy. The primary focus is the successful execution of the Annual Meeting agenda items.
Key Facts for Investor Verification
- Verify the dilution impact of the increased stock option pool (now 30 million shares authorized) on existing shareholders.
- Confirm the terms of the newly elected directors' compensation and tenure in the definitive proxy statement filed September 26, 2025.
- Review the full text of the Stock Incentive Plan Amendment filed as Exhibit 10.1 to this 8-K.
- Check the most recent quarterly or annual report for the Company's actual financial health, as this 8-K contains no financial data.